Volume 18, Number 4—April 2012
Dispatch
Human Parvovirus 4 Infection, Cameroon
Myriam Lavoie, Colin P. Sharp, Jacques Pépin
, Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter Simmonds
, Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter SimmondsTable 2
Correlates of study participants and human parvovirus 4 infection in multivariate analysis, Cameroon, 2009
| Participant characteristic | All participants |
After exclusions* |
|||
|---|---|---|---|---|---|
| Adjusted odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value | ||
| Age group, y | |||||
| 60–64 | 2.21 (1.13–4.31) | 0.02 | 2.88 (1.16–7.17) | 0.02 | |
| 65–69 | 1.01 (0.46–2.24) | 0.98 | 1.20 (0.39–3.70) | 0.76 | |
| 70–74 | 1.16 (0.54–2.46) | 0.71 | 1.51 (0.55–4.16) | 0.42 | |
| >75 | 1.00 | 1.00 | |||
| Tuberculosis | |||||
| No | 1.00 | 1.00 | |||
| Yes, treated with oral drugs only | 2.09 (0.58–7.54) | 0.26 | 2.91 (0.63–13.51) | 0.17 | |
| Yes, treatment included streptomycin | 5.21 (0.99–27.37) | 0.05 | 20.96 (1.67–262.99) | 0.02 | |
| Vaccine scar, left arm | |||||
| Absent | 1.00 | 1.00 | |||
| Present | 0.37 (0.19–0.71) | 0.003 | 0.32 (0.13–0.78) | 0.01 | |
| Intravenous treatment for malaria | 0.06 | ||||
| No | 1.00 | 1.00 | |||
| Yes | 1.92 (1.13–3.24) | 0.015 | 1.98 (0.97–4.03) | 0.06 | |
*After exclusion of 81 participants with borderline negative results and 35 with borderline positive results.
